Wave Life Sciences Management
Management criteria checks 3/4
Wave Life Sciences' CEO is Paul B. Bolno, appointed in Dec 2013, has a tenure of 10.92 years. total yearly compensation is $3.87M, comprised of 16.4% salary and 83.6% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $3.24M. The average tenure of the management team and the board of directors is 3.9 years and 8 years respectively.
Key information
Paul B. Bolno
Chief executive officer
US$3.9m
Total compensation
| CEO salary percentage | 16.4% |
| CEO tenure | 10.9yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.9yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results
Nov 15
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking
Nov 09Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Oct 16There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Sep 25Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Sep 24Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Sep 08We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
Aug 05Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
Jun 25We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$143m |
| Jun 30 2024 | n/a | n/a | -US$73m |
| Mar 31 2024 | n/a | n/a | -US$62m |
| Dec 31 2023 | US$4m | US$636k | -US$58m |
| Sep 30 2023 | n/a | n/a | -US$85m |
| Jun 30 2023 | n/a | n/a | -US$131m |
| Mar 31 2023 | n/a | n/a | -US$151m |
| Dec 31 2022 | US$3m | US$618k | -US$162m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$118m |
| Dec 31 2021 | US$4m | US$597k | -US$122m |
| Sep 30 2021 | n/a | n/a | -US$116m |
| Jun 30 2021 | n/a | n/a | -US$143m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$1m | US$579k | -US$150m |
| Sep 30 2020 | n/a | n/a | -US$178m |
| Jun 30 2020 | n/a | n/a | -US$196m |
| Mar 31 2020 | n/a | n/a | -US$197m |
| Dec 31 2019 | US$4m | US$579k | -US$194m |
| Sep 30 2019 | n/a | n/a | -US$175m |
| Jun 30 2019 | n/a | n/a | -US$162m |
| Mar 31 2019 | n/a | n/a | -US$156m |
| Dec 31 2018 | US$6m | US$541k | -US$147m |
| Sep 30 2018 | n/a | n/a | -US$140m |
| Jun 30 2018 | n/a | n/a | -US$127m |
| Mar 31 2018 | n/a | n/a | -US$116m |
| Dec 31 2017 | US$3m | US$515k | -US$102m |
Compensation vs Market: Paul B.'s total compensation ($USD3.87M) is below average for companies of similar size in the US market ($USD5.54M).
Compensation vs Earnings: Paul B.'s compensation has increased whilst the company is unprofitable.
CEO
Paul B. Bolno (50 yo)
10.9yrs
Tenure
US$3,874,300
Compensation
Dr. Paul B. Bolno, M.D., MBA served as an Independent Director at SQZ Biotechnologies Company since June 2020 until March 2024. Since May 2020 he has served as Chairman of the Scientific Advisory Group for...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.9yrs | US$3.87m | 0.14% $ 3.2m | |
| CFO & Principal Accounting Officer | 3.9yrs | US$1.70m | 0.029% $ 666.8k | |
| Chief Technology Officer | 4.5yrs | US$1.78m | 0.12% $ 2.8m | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Head of Investor Relations | 5.6yrs | no data | no data | |
| Senior VP & General Counsel | 8.5yrs | no data | no data | |
| Senior VP of Corporate Development & Head of Emerging Areas | 7.8yrs | US$1.68m | 0% $ 0 | |
| Senior VP & Head of Human Resources | 1.8yrs | no data | no data | |
| Senior Vice President of Chemistry | 3yrs | no data | no data | |
| Chief Development Officer | 2.1yrs | no data | no data | |
| Senior Vice President of Translational Medicine | 1.8yrs | no data | no data |
3.9yrs
Average Tenure
51.5yo
Average Age
Experienced Management: WVE's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.6yrs | US$3.87m | 0.14% $ 3.2m | |
| Director | 11.3yrs | US$170.74k | 0.020% $ 446.7k | |
| Independent Director | 5.2yrs | US$194.74k | 0.078% $ 1.8m | |
| Independent Chairperson | 8yrs | US$222.24k | 0.085% $ 1.9m | |
| Independent Director | 7.8yrs | US$188.74k | 0.085% $ 1.9m | |
| Independent Director | 9.8yrs | US$170.74k | 0% $ 0 | |
| Independent Director | 12.3yrs | US$170.74k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$185.74k | 0.078% $ 1.8m | |
| Independent Director | 4.3yrs | US$172.24k | 0.069% $ 1.6m |
8.0yrs
Average Tenure
56yo
Average Age
Experienced Board: WVE's board of directors are considered experienced (8 years average tenure).